The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What…
In Conversation
It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS…
¿Cual fue la visión de la creación de ANMAT y las circunstancias de su creación? En el momento de la creación del ANMAT, el Gobierno Nacional…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What…
There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local…
This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last…
This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now…
The pharmaceutical industry in Asia is undergoing a period of specialization with R&D booming in places like Australia, Singapore and South Korea and manufacturing in places…
Mr. Sardi, Exec-VP of Tecnoquímicas, the No. 1 producer and distributor of generic pharmaceutical drugs in Colombia, explains what makes Tecnoquímicas different from their contemporaries and…
¿Cual fue la visión detrás de la creación de IBC y Dromex? Nuestro negocio original consistía en representar comercialmente a los fabricantes de APIs europeos. Esto…
